In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Biomerica onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:BMRA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
5/31/2024	5	-6	-5	-5	N/A
2/29/2024	5	-6	-5	-5	N/A
11/30/2023	6	-6	-5	-5	N/A
8/31/2023	5	-6	-6	-6	N/A
5/31/2023	5	-7	-6	-5	N/A
2/28/2023	10	-7	-9	-9	N/A
11/30/2022	16	-6	-5	-5	N/A
8/31/2022	19	-5	-2	-2	N/A
5/31/2022	19	-5	-1	0	N/A
2/28/2022	15	-4	3	3	N/A
11/30/2021	11	-7	-1	-1	N/A
8/31/2021	7	-7	-4	-4	N/A
5/31/2021	7	-7	-6	-5	N/A
2/28/2021	9	-6	-8	-8	N/A
11/30/2020	6	-5	-7	-7	N/A
8/31/2020	7	-4	-6	-6	N/A
5/31/2020	7	-2	-4	-4	N/A
2/29/2020	5	-3	-2	-2	N/A
11/30/2019	5	-2	-2	-2	N/A
8/31/2019	5	-2	-2	-1	N/A
5/31/2019	5	-2	-2	-2	N/A
2/28/2019	5	-2	-2	-2	N/A
11/30/2018	5	-2	-2	-2	N/A
8/31/2018	5	-2	-2	-2	N/A
5/31/2018	6	-1	-1	-1	N/A
2/28/2018	6	-1	N/A	-1	N/A
11/30/2017	6	-1	N/A	-1	N/A
8/31/2017	6	-1	N/A	-1	N/A
5/31/2017	6	-1	N/A	-1	N/A
2/28/2017	6	-2	N/A	0	N/A
11/30/2016	6	-2	N/A	0	N/A
8/31/2016	5	-1	N/A	0	N/A
5/31/2016	5	-1	N/A	0	N/A
2/29/2016	5	0	N/A	0	N/A
11/30/2015	5	0	N/A	-1	N/A
8/31/2015	5	0	N/A	-1	N/A
5/31/2015	5	0	N/A	0	N/A
2/28/2015	5	0	N/A	0	N/A
11/30/2014	5	0	N/A	0	N/A
8/31/2014	5	0	N/A	0	N/A
5/31/2014	5	0	N/A	-1	N/A
2/28/2014	5	0	N/A	-1	N/A
11/30/2013	5	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van BMRA boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van BMRA naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van BMRA naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van BMRA naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van BMRA naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van BMRA naar verwachting over 3 jaar hoog zal zijn

Biomerica Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Price target increased to US$13.00

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Analysts lower revenue estimates to US$8.51m

Recent updates

Biomerica, Inc., Annual General Meeting, Dec 13, 2024

New major risk - Financial position

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers

Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

Biomerica, Inc. has filed a Follow-on Equity Offering in the amount of $5.5 million.

Biomerica Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Biomerica clinical trial for IBS nears enrollment completion

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Analysts update estimates